Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Adenocarcinoma of the Bladder 1

Interventions

Specimen Handling 6cabozantinib 4Magnetic Resonance Spectroscopy 4Trastuzumab 3Gemcitabine 3Biopsy 3eribulin 2atezolizumab 2Nivolumab 2Ipilimumab 2CTLA-4 Antigen 2tipifarnib 1pazopanib 1ixabepilone 1erdafitinib 1entinostat 1enfortumab vedotin 1avelumab 1aflibercept 1Sunitinib 1Sorafenib 1Platinum 1Lenalidomide 1Interleukin-7 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urethral Neoplasms × enfortumab vedotin × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡